Catalyst will receive $11 million for its Alterase technology to be used against inflammatory diseases and at least one other target.
Catalyst Biosciences will use its Alterase™ therapeutics in an exclusive, worldwide research and license agreement with Centocor Research & Development. Alterase therapeutics are protease biologics engineered with the ability to catalytically cleave and inactivate disease-causing proteins.
Under terms of the collaboration, Centocor will support Catalyst’s discovery research and preclinical development of Alterase drug candidates against two targets, one of them inflammatory disease. Centocor may expand the agreement to include a third target.
Catalyst Biosciences will receive an upfront payment of $11 million, which includes both cash and an equity investment by Johnson & Johnson. They will also obtain additional research funding for two years.
Centocor will be responsible for all development, manufacturing, and commercialization efforts associated with the Alterase products discovered through the collaboration in exchange for future milestones and royalties.
